Table 2 Subsequent therapy use in AXIS and METEOR
Trial | AXIS | METEOR | METEOR |
|---|---|---|---|
Arm | Axitinib, prior sunitinib-treated patients (N = 194) | Cabozantinib, prior sunitinib-treated patients (N = 135) | Everolimus, prior sunitinib-treated patients (N = 132) |
Any systemic therapy, % | 60 | 48 | 55 |
 Axitinib | 0 | 18 | 39 |
 Pazopanib | 5 | 3 | 7 |
 Sunitinib | 7 | 2 | 3 |
 Sorafenib | 20 | 2 | 7 |
 Cabozantinib | 0 | 0 | 2 |
 Everolimus | 43 | 25 | 4 |
 Bevacizumab | 8 | 2 | 2 |
 Anti-PD-1/PD-L1 | 0 | 2 | 4 |